Mainz Biomed Provides Year-End Corporate Review 2023
Mainz Biomed Provides Year-End Corporate Review 2023...
Stay updated with breaking news from Microba Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mainz Biomed Provides Year-End Corporate Review 2023...
The company its brokers Bell Potter and Morgans rounding up offers at 23¢ a piece.
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving diagnostics. For example, Mainz Biomed (NASDAQ: MYNZ) has developled ColoAlert, an affordable test for early detection of Colorectal cancer. As a company specializing in molecular genetic diagnostic solutions for life-threatening conditions, Mainz Biomed also partnered with Microba Life Sciences, a compa
The WHO reports that colorectal cancer is the second most fatal cancer around the world.
Microba Life Sciences ( ASX:MAP ) Full Year 2023 Results Key Financial Results Revenue: AU$5.42m (up 16% from FY 2022...